Project Grant R41TR002298

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...

Award Summary Orion Therapeutics Inc. received a $1.25M Small Business Technology Transfer (STTR) Phase II Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084), awarded September 15, 2025, with completion targeted for August 31, 2027. The project focuses on developing and advancing a multifunctional lipid nanoparticle (LNP) delivery platform designed to enable safe and targeted delivery of RNA therapeutics to specific...

Nano Pharmasolutions, Inc. received a $275,961 Project Grant award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041). The grant funds the development of a novel nanoformulation drug delivery platform to address challenges associated with poorly soluble drugs. The goal is to improve drug solubility and bioavailability through innovative formulation approaches. The one-year project period runs from August 1, 2021...

The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...

Gateway Bio Inc. received a $628,694 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 23, 2025, with completion expected by August 31, 2026. The project focuses on developing a next-generation lipid nanoparticle (LNP) delivery system featuring a proprietary polyethylene glycol (PEG) alternative called poly(oligoethylene glycol) methyl ether methacrylate (POEGMA) for...

This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...

Kinea Bio Inc. received a $306,859 Project Grant Award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 15, 2025, with completion targeted for August 31, 2026. The award funds development of a scalable, non-viral gene delivery therapeutic platform using cell-derived nanovesicles to treat myotonic dystrophy type 1 (DM1), the most common adult-onset...

This SBIR Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program seeks to develop a new class of gene therapies that can be delivered more safely, cost-effectively, and at scale for a wide range of serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible...

The National Institute of Allergy and Infectious Diseases awarded a Project Grant of $118,332 to the University of North Carolina at Charlotte under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the development of multifunctional RNA/DNA nanoassemblies capable of therapeutic immune pathway activation. The project, initiated on October 9, 2026, and scheduled for completion by January 31, 2029, focuses on engineering hybrid RNA/DNA nanostructures that can simultaneously...

Federal Project Grant Award Summary Nanoengineering Corporation received a $349,909 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded July 1, 2025, with a completion date of June 30, 2027. The award funds commercial development of the NanoRanger, a portable benchtop instrument utilizing proprietary Electrospray Differential Mobility Analysis (ES-DMA) technology licensed from Yale University. This tool provides angstrom-scale resolution...